Recent Finacing
Recent Raise
Knopp Biosciences develops small-molecule therapeutics—clinical‑stage oral dexpramipexole for eosinophilic asthma and other indications—and a preclinical Kv7/KCNQ2 program advancing IND‑enabling studies toward first‑in‑human trials.
